Details of the Drug
General Information of Drug (ID: DMLG69R)
Drug Name |
3-Fluoro-4-hydrazino-benzenesulfonamide
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
3-Fluoro-4-hydrazino-benzenesulfonamide; 606126-17-4; 3-fluoro-4-hydrazinobenzenesulfonamide; hydrazide deriv. 15; SCHEMBL1244816; CHEMBL176180; CTK2E9801; BDBM12160; DTXSID90448811; IDSRHQBHQWPDNY-UHFFFAOYSA-N; AKOS013645919; 4-Hydrazino-3-fluorobenzenesulfonamide; Benzenesulfonamide, 3-fluoro-4-hydrazino-; TC-063144; 3-fluoro-4-hydrazinylbenzene-1-sulfonamide; 144147-EP2287165A2; 144147-EP2292620A2
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 205.21 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | -0.2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 3 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 6 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||||||||